Owlstone Nanotech Appoints Bret Bader as CEO; Security Technology Veteran to Provide Strategic Direction as Owlstone Continues to Grow Operations
"Bret is a decisive, market-driven business leader," said Andrew Koehl, co-founder and President of Owlstone Nanotech, Inc. "He will be an incredible asset to our leadership team as we seek new business partners and get our technology into the hands of the user community. We will rely on his experience and seasoned leadership during this exciting period in Owlstone's history."
“Bret is a decisive, market-driven business leader”
Prior to joining Owlstone, Mr. Bader held several leadership positions with Smiths Detection, the leading manufacturer of security screening sensors for the detection of explosives, narcotics, weapons and chemical and biological warfare agents, and a subsidiary of Smiths Group Plc (LSE:SMIN.L). Most recently he served as general manager and vice president of the Americas division. He directed all sales and support activities in the U.S., developed and implemented all business-marketing plans and oversaw accounting and controller functions. Mr. Bader also held positions of general manager and vice president of the civil business division, and general manager of the security inspection division.
Before Smiths Detection, Mr. Bader held the positions of regional sales manager, national sales manager, and director of sales for EG&G Astrophysics, a U.S. manufacturer of x-ray security screening technology. Mr. Bader attended the University of Massachusetts, Amherst.
"I am convinced that the Owlstone technology will change the way we design, deploy and utilize detection sensors in the safety and security markets," said Mr. Bader, regarding his appointment. "I am thrilled to bring my knowledge and experience to this exceptional team."
About Owlstone Nanotech, Inc.
Owlstone Nanotech is a pioneer in the commercialization of nanotechnology-based chemical detection products. Its initial commercial product, The Owlstone Detector, is a revolutionary dime-sized device that can be programmed to detect a wide range of chemical agents that may be present in extremely small quantities. Using leading-edge micro- and nano-fabrication techniques, Owlstone has created a complete chemical detection system a hundred times smaller and a thousand times cheaper than existing technology. There are numerous applications -- across industries from security and defense to automotive and healthcare -- that depend on the rapid, accurate detection and measurement of chemical compounds. Owlstone works with market leaders within these applications to integrate the detector into next generation chemical sensing products and solutions. Owlstone's technology offers a unique combination of benefits, including: small size, low manufacturing costs, minimal power consumption, reduced false-positives, and a customizable platform. For more information on Owlstone Nanotech, please visit www.owlstonenanotech.com.
About Advance Nanotech, Inc.
Advance Nanotech is dedicated to the successful commercialization of disruptive nanotechnologies to produce nano-enabled products. Advance provides financing and support services including commercialization guidance, project and infrastructure management, leadership assets, and counsel on intellectual property, licensing and regulatory issues to ensure maximum market potential. Advance Nanotech's diversified portfolio of 26 nanotechnologies, of which the company holds a majority stake in 21, impacts a range of applications including, but not limited to, sensors, medical therapeutics and composites. Advance is forging partnerships with leading manufacturers and universities in Europe, Asia and North America to transform innovative nanotechnology concepts into practical solutions. For more information on Advance Nanotech, please visit www.advancenanotech.com.
This document contains forward-looking statements by Advance Nanotech regarding its expectations as to its business, and involves risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those addressed in the forward-looking statements.
Factors that may cause such a difference include, but are not limited to, problems and risks associated with developments in the nanotechnology industry in general and in Advance Nanotech's products under development in particular; the potential failure of Advance Nanotech's products under development to prove safe and effective in application; uncertainties inherent in the early stage of Advance Nanotech's products under development; failure to successfully implement or complete research programmes; failure to receive marketing clearance from regulatory agencies for our products under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Advance Nanotech's business, structure or projections; the development of competing products; uncertainties related to Advance Nanotech's dependence on third parties and partners; and those risks described Advance Nanotech's filings with the SEC. Advance Nanotech disclaims any obligation to update these forward-looking statements.
Further information about these and other relevant risks and uncertainties may be found in the Advance Nanotech's findings with the Securities and Exchange Commission, all of which are available from the Commission as well as other sources.